"Charles Retina Institute is one of the world’s foremost retinal clinics, specializing in vitreoretinal diseases and surgery. We specialize in the treatment of retinal detachment, proliferative vitreoretinopathy, macular holes, diabetic retinopathy, age-related macular degeneration, epimacular membranes, retinopathy of prematurity, as well as other macular and vitreous problems."

During the past decade, Charles Retina Institute conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 11 clinical trials were completed, i.e. on average, 32.4% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 10 clinical trials were completed. i.e. 47.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Charles Retina Institute" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Genentech, Inc." with 7 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored, "Gyroscope Therapeutics Limited" with 2 trials sponsored and "Kodiak Sciences Inc" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Charles Retina Institute" #1 collaborator was "Chugai Pharmaceutical" with 2 trials as a collaborator, "Novartis Pharmaceuticals" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator and "Clinical Trials Resource Group, LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Charles Retina Institute" are "Diabetic Macular Edema" (6 trials), "Geographic Atrophy" (6 trials), "Macular Edema" (4 trials), "Diabetic Retinopathy" (3 trials) and "Macular Degeneration, Age-Related" (3 trials). Many other conditions were trialed in "Charles Retina Institute" in a lesser frequency.

Most popular intervention types in "Charles Retina Institute" are "Drug" (31 trials), "Other" (8 trials), "Procedure" (5 trials), "Combination Product" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Faricimab" (11 trials), "Sham Procedure" (10 trials), "Aflibercept" (5 trials), "Ranibizumab" (5 trials) and "Lampalizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Charles Retina Institute" are 34 trials for "All" genders.

Currently, there are NaN active trials in "Charles Retina Institute". undefined are not yet recruiting, 5 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Charles Retina Institute, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Charles Retina Institute, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".